1H-NMR-based urine metabolomics of prostate cancer and benign prostatic hyperplasia

dc.contributor.authorZniber, Mohammed
dc.contributor.organizationfi=biolääketieteen laitos|en=Institute of Biomedicine|
dc.contributor.organization-code1.2.246.10.2458963.20.97295082107
dc.converis.publication-id387534372
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/387534372
dc.date.accessioned2025-08-27T23:03:51Z
dc.date.available2025-08-27T23:03:51Z
dc.description.abstract<p><strong>Background and aims: </strong>Atherosclerosis is accompanied by pre-clinical vascular changes that can be detected using ultrasound imaging. We examined the value of such pre-clinical features in identifying young adults who are at risk of developing atherosclerotic cardiovascular disease (ASCVD).</p><p><strong>Methods: </strong>A total of 2641 individuals free of ASCVD were examined at the mean age of 32 years (range 24-45 years) for carotid artery intima-media thickness (IMT) and carotid plaques, carotid artery elasticity, and brachial artery flow-mediated endothelium-dependent vasodilation (FMD). The average follow-up time to event/censoring was 16 years (range 1-17 years).</p><p><strong>Results: </strong>Sixty-seven individuals developed ASCVD (incidence 2.5%). The lowest incidence (1.1%) was observed among those who were estimated of having low risk according to the SCORE2 risk algorithm (<2.5% 10-year risk) and who did not have plaque or high IMT (upper decile). The highest incidence (11.0%) was among those who were estimated of having a high risk (≥2.5% 10-year risk) and had positive ultrasound scan for carotid plaque and/or high IMT (upper decile). Carotid plaque and high IMT remained independently associated with higher risk in multivariate models. The distributions of carotid elasticity indices and brachial FMD did not differ between cases and non-cases.</p><p><strong>Conclusions: </strong>Screening for carotid plaque and high IMT in young adults may help identify individuals at high risk for future ASCVD.</p>
dc.identifier.eissn2405-8440
dc.identifier.olddbid203315
dc.identifier.oldhandle10024/186342
dc.identifier.urihttps://www.utupub.fi/handle/11111/32487
dc.identifier.urlhttps://doi.org/10.1016/j.heliyon.2024.e28949
dc.identifier.urnURN:NBN:fi-fe2025082790070
dc.language.isoen
dc.okm.affiliatedauthorLamminen, Tarja
dc.okm.affiliatedauthorTaimen, Pekka
dc.okm.affiliatedauthorBoström, Peter
dc.okm.affiliatedauthorDataimport, tyks, vsshp
dc.okm.discipline318 Medical biotechnologyen_GB
dc.okm.internationalcopublicationnot an international co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherElsevier
dc.publisher.countryUnited Kingdomen_GB
dc.publisher.countryBritanniafi_FI
dc.publisher.country-codeGB
dc.relation.articlenumbere28949
dc.relation.doi10.1016/j.heliyon.2024.e28949
dc.relation.ispartofjournalHeliyon
dc.relation.issue7
dc.relation.volume10
dc.source.identifierhttps://www.utupub.fi/handle/10024/186342
dc.title1H-NMR-based urine metabolomics of prostate cancer and benign prostatic hyperplasia
dc.year.issued2024

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
1-s2.0-S2405844024049806-main.pdf
Size:
2.55 MB
Format:
Adobe Portable Document Format